Rare Gene Variant May Shield APOE4 Carriers From Alzheimer’s
Scientists studied people who carry APOE4, a major Alzheimer’s risk variant, but remain cognitively healthy into their 80s. They found that a rare mutation in the FN1 gene appears to reduce fibronectin accumulation around brain blood vessels, helping preserve the blood-brain barrier. The work, published in Nature Aging, outlines a mechanism that might be targeted to prevent early Alzheimer’s damage.
The study follows earlier work that linked a rare FN1 mutation to protection in some APOE4 carriers. Fibronectin normally helps hold tissues together, but excess protein around brain vessels may weaken the blood-brain barrier in APOE4 carriers.
Columbia researchers combined human brain tissue and cerebrospinal fluid analyses with genetic, epigenetic, and single-cell sequencing. Published in Nature Aging, the work describes how fibronectin buildup may harm the barrier and suggests ways to mimic the mutation’s protective effect.
If confirmed, this finding could matter most to APOE4 carriers and families concerned about inherited Alzheimer’s risk. A therapy mimicking the FN1 mutation might one day help preserve the blood-brain barrier and delay early damage, potentially extending cognitively healthy years. However, clinical benefit remains uncertain and may require substantial further testing. It may also inform prevention research and genetic counseling, though it may not address all causes of dementia.